Ice treatment for kidney cancer shows promise in latest trial

NCT ID NCT02399124

Ongoing Disease control Sponsor: IceCure Medical Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called PROSENSE™ that freezes kidney tumors to destroy them. It involves 120 adults with small kidney cancers (up to 5 cm). The goal is to see if the freezing completely covers the tumor and prevents it from coming back over 5 years. The approach is minimally invasive and aims to control the disease without major surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cryotherapy (freezing) using the PROSENSE™ device
What this could lead to: If successful, this could provide a minimally invasive option to control kidney cancer without surgery, potentially reducing recurrence.
What could go wrong: This is a post-market data collection study, not a randomized trial, so results may not prove superiority over standard treatments. Risks include incomplete tumor freezing or complications like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

Bnei Zion Medical Center

Haifa, Israel
Shamir Medical Center

Ẕerifin, 70300, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.